Regulatory and trial progress: TSHA-102 received FDA Breakthrough Therapy designation, Taysha has initiated the REVEAL pivotal trial and obtained clearance for the safety-focused ASPIRE study, with FDA alignment supporting pooling of clinical data and a PPQ plan to enable a BLA submission.

Encouraging safety and efficacy signals: REVEAL Part A showed strong responses—100% response across 10 treated patients and 83% response at six months in the high-dose cohort—while management reported no treatment-related serious adverse events to the March 2026 cutoff; 12‑month follow-up data are due in Q2 2026.

Financial runway and commercial readiness: 2025 net loss widened to $109.0 million on higher R&D/G&A, but Taysha ended the year with $319.8 million in cash plus $50 million raised in Q4, which management says funds operations into 2028 as it builds market access and prepares for potential commercialization (favoring intrathecal delivery).

Interested in Taysha Gene Therapies, Inc.? Here are five stocks we like better.

Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Taysha Gene Therapies (NASDAQ:TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wider net loss for full-year 2025, according to management on the company’s March 19 conference call.

Chief Executive Officer Sean Nolan said 2025 was “a year of significant execution,” pointing to Phase I/II REVEAL data across pediatric, adolescent, and adult patients, the FDA’s Breakthrough Therapy designation for TSHA-102, and written FDA alignment on the REVEAL pivotal and ASPIRE trial designs. Nolan said those steps “pav[e] the way for a potentially streamlined path toward BLA submission.”

→ Dollar Tree Planted the Seeds for Triple-Digit Gains in Q4

3 Small-Cap Stocks For Your Fall Shopping List

The company initiated the REVEAL pivotal trial in the fourth quarter of 2025 with dosing of the first patient. Nolan said multiple patients have now been dosed, enrollment is advancing across multiple sites, and Taysha remains on track to complete dosing in the second quarter of 2026.

Management also emphasized tolerability across studies to date. Nolan said both high- and low-dose TSHA-102 have continued to be generally well-tolerated, with no treatment-related serious adverse events or dose-limiting toxicities observed in patients treated in the REVEAL Phase I/II and REVEAL pivotal trials as of the March 2026 data cutoff.

→ Why Credo and Astera Soared After Oracle and Broadcom's Earnings

Taysha recently received FDA clearance to initiate ASPIRE, a safety-focused trial intended to support a broad label for TSHA-102 in patients aged two years and older. Nolan said ASPIRE will enroll three females with Rett syndrome aged two to less than four years and evaluate safety and preliminary efficacy after a single intrathecal administration of the high dose (1e15 total vector genomes), scaled to account for lower brain volume in younger patients.

According to Nolan, written FDA alignment indicates the planned BLA submission will include a minimum of three months of ASPIRE safety data, while efficacy in the two- to less-than-six population would be extrapolated from the REVEAL pivotal trial to support a broad label. Taysha expects to complete dosing for ASPIRE in the second quarter of 2026.

→ Joby Aviation’s Golden Gate Flight Signals a New Era for eVTOL

During the Q&A, management said ASPIRE represented a “pleasant surprise” in that the FDA wanted the company to focus on safety in two- and three-year-olds rather than enrolling up to less than six years, citing brain volume considerations and comfort with data in older patients.

Nolan said the company held a Type C meeting with the FDA in the first quarter of 2026 and reached written alignment on chemistry, manufacturing, and controls (CMC) requirements for the planned BLA submission. He said FDA agreed Taysha’s proposed comparability approach between clinical and final commercial manufacturing processes “may support pooling data” from REVEAL Phase I/II, the ongoing REVEAL pivotal trial, and ASPIRE for the planned BLA submission.

Nolan also said FDA endorsed Taysha’s process performance qualification (PPQ) campaign strategy for process validation, including the stability data package, potency assay strategy, and execution of BLA-enabling PPQ lots using the commercial manufacturing process, which the company expects to initiate in the second quarter of 2026. In response to an analyst question, CFO Kamran Alam said PPQ lots are expected to be completed by the end of 2026.

On timing around a potential BLA following the pivotal interim analysis, Nolan said the interim analysis is planned once all pivotal patients are at six months post-dose, with unblinding dependent on the last patient being dosed (which the company continues to track to the second quarter of 2026). Nolan said Taysha plans to meet with the FDA before updating the market, arguing that any next steps would depend on FDA feedback. He outlined possible outcomes ranging from an agency recommendation to file on six-month data to requests for longer follow-up, while noting that the company is preparing other components of the submission in parallel.

President and Head of R&D Sukumar Nagendran reiterated previously presented REVEAL Part A Phase I/II results and said the company remains encouraged by the data and the FDA-aligned pathway. He said Part A demonstrated a 100% response rate across 10 treated patients across both dose cohorts. In the high-dose cohort, he said an 83% response rate was seen at six months post-treatment, with five of six patients gaining or regaining one or more predefined developmental milestones; by nine months post-treatment, he said the high-dose cohort showed a 100% response rate.

Nagendran also cited additional functional progress, stating that alongside 22 developmental milestones gained, patients demonstrated 165 other skill gains and improvements across core Rett syndrome domains, averaging about 19 gains per patient, as captured by validated clinical assessments. He said the company has observed early gains that are sustained with additional gains over time.

Taysha expects to report longer-term safety and efficacy data across all 12 pediatric, adolescent, and adult patients treated in REVEAL Part A in the second quarter of 2026, when all patients will have reached 12-month follow-up timepoints. Nolan said the update will include milestones as the primary endpoint as well as other measures such as CGIs and RMBA, and that the first patient dosed will be roughly three years post-dose by that time, providing durability data.

Nagendran also pointed to a publication by Dr. Jeffrey Neul and investigators from the NIH-funded IRSF Rett Syndrome Natural History Study, which he said provides a comprehensive longitudinal view of milestone gain, loss, and regain in Rett syndrome. He highlighted findings that the combined likelihood of spontaneous milestone gain or regain dropped to 6.3% after age six, compared to rates as high as 85% between ages one and five. He said the company’s FDA-aligned REVEAL pivotal trial is enrolling 15 patients aged six to less than 22 years, with a design that tests response rate against a low null hypothesis of 6.7% and requires a minimum 30% response rate to demonstrate efficacy.

Taysha said it continued building commercial readiness alongside clinical development. Nolan described Rett syndrome as a rare and progressive neurodevelopmental condition with high unmet need and said there are an estimated 15,000 to 20,000 patients across the U.S., E.U., and U.K., with 6,000 to 9,000 patients estimated in the U.S. based on claims and epidemiology data.

Nolan said market research showed high anticipated demand among clinicians and caregivers and “a clear preference for intrathecal administration” versus direct-to-brain delivery, citing familiarity, accessibility, and scalability. He said intrathecal delivery could potentially be performed as a routine, minimally invasive outpatient procedure that does not require a surgical suite or neurosurgery expertise, which he argued could broaden access beyond centers of excellence.

In the Q&A, Nolan said roughly 50% of Rett patients are associated with a center of excellence (defined as at least one visit per year), suggesting a substantial population outside those centers. He also said both caregivers and clinicians take a pragmatic view that if clinical outcomes are similar across approaches, they prefer the least invasive route.

The company also announced a commercial leadership hire, naming Brad Martin as Senior Vice President of Market Access and Value. Nolan said Martin brings gene therapy market access experience from Neurotech Pharmaceuticals, Sarepta Therapeutics, and AveXis, including involvement in access for Zolgensma. Nolan said the market access function will focus on mapping where patients are, payer mix, sequencing site rollout and training, and early engagement with payers to educate them on disease burden and the company’s data.

Alam reported that research and development expenses were $86.4 million for the year ended Dec. 31, 2025, compared to $66.0 million in 2024, driven primarily by higher compensation from increased R&D headcount, along with increased clinical trial and GMP expenses related to REVEAL activities and BLA-enabling PPQ manufacturing initiatives.

General and administrative expenses were $33.9 million in 2025, compared to $29.0 million in 2024, reflecting higher compensation, higher legal and professional fees, and debt issuance costs related to the 2025 Trinity term loan recorded under the fair value option.

Net loss was $109.0 million, or $0.34 per share, in 2025, compared to a net loss of $89.3 million, or $0.36 per share, in 2024. As of Dec. 31, 2025, Taysha had $319.8 million in cash and cash equivalents. Alam said the company raised $50 million in gross proceeds during the fourth quarter through its at-the-market equity program, with proceeds intended to support a potential commercial inventory build in 2027, and said current cash resources are expected to fund operating expenses into 2028.

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

The article "Taysha Gene Therapies Q4 Earnings Call Highlights" was originally published by MarketBeat.